Baseline characteristics of the cohort
| Probable AD (n=107) | Probable DLB (n=67) | p Value | |
|---|---|---|---|
| Age | 75.1 (7–9) | 76.1 (7–2) | 0.598 |
| Female, N (%) | 80 (74.8) | 32 (47.8) | <0.0005 |
| Education, years, mean, SD | 9.8 (3.0) | 9.5 (2.7) | 0.512 |
| CDR global score, median, IQR | 1.00 (0.50) | 1.00 (0.50) | 0.217 |
| MMSE total score, mean, SD | 23.6 (2.3) | 23.5 (3.0) | 0.870 |
| Duration of symptoms before baseline, years, mean, SD | 2.0 (2.0) | 2.6 (1.9) | 0.011 |
| NPI total scores, mean, SD | 15.7 (16.9) | 22.8 (19.1) | 0.006 |
| CIRS score, mean, SD | 5.1 (2.1) | 6.3 (2.6) | 0.004 |
| UPDRS III scores, mean, SD | 1.5 (2.3) | 14.2 (13.0) | <0.0005 |
| Antipsychotics, N (%) | 4 (3.7) | 10 (14.9) | 0.008 |
| Antiparkinsonian medication, N (%) | 0 (0) | 9 (13.4) | <0.005 |
| Antidementia medication, N (%) | 68 (63.6) | 38 (56.7) | 0.436 |
| Death during follow-up, N (%) | 59 (55.1) | 52 (77.6) | 0.003 |
AD, Alzheimer's dementia; CDR, Clinical Dementia Rating; CIRS, Cumulative Illness Rating Scale; DLB, Dementia with Lewy bodies; MMSE, Mini-Mental State Examination; N, number; NPI, Neuropsychiatric Inventory; UPDRS, Unified Parkinson's Disease Rating Scale-motor subscale.